Cardiogen

Cardiogen Overview

Cardiogen is a bioregulatory tetrapeptide with the sequence Ala-Glu-Asp-Arg, promoted for cardiovascular support. The proposed mechanism is stimulation of fibroblast proliferation and protein synthesis in heart muscle, achieved by influencing the expression of genes tied to myocardial remodeling and cellular repair. It is mainly positioned for recovery after cardiac injury and for slowing age-related deterioration of heart tissue. As a peptide, it is sold as a research chemical requiring reconstitution and subcutaneous injection, and purity and storage matter.

Editorial Verdict

Cardiogen belongs to the family of Russian "bioregulator" peptides whose marketing tends to outrun the published evidence. The idea is mechanistically tidy, but the supporting research is thin and dominated by cell-culture work. There are no human randomized trials to demonstrate that injecting this peptide improves heart outcomes in real patients.

Evidence Quality

We assign a research grade of C. This rests on 8 peer-reviewed studies: 1 observational, 1 animal, 4 in vitro, and 1 review. Of the 8 classified findings, 6 were supportive and 2 were mixed. Crucially, there are no RCTs or meta-analyses in humans, so the evidence base is preliminary.

What the Research Shows

The available work describes targeted action on cardiovascular tissue with little reported impact on other organ systems. It is often presented as more useful in a preventive or restorative role for chronic conditions than as an acute performance booster, and is sometimes paired with other bioregulators such as Epitalon on the claim of added benefit. These synergy claims are not backed by controlled human data.

Dosage

The commonly cited protocol is 1-5 mg daily by subcutaneous injection for 10-20 days. An oral capsule form exists but is generally regarded as having lower bioavailability than the injectable. Users tend to run it in periodic cycles, roughly two to three times per year, rather than continuously.

Who Should Be Cautious

Expected issues are mild: redness or soreness at the injection site, rare anecdotal reports of short-lived blood pressure changes at the start of a cycle, and the general possibility of minor allergic reactions to any foreign peptide.

Availability

Cardiogen is sold mainly through online peptide vendors labeled "for research purposes only." It is not FDA-approved for medical treatment in the United States, though it is used clinically in some other regions such as Russia.

Bottom Line

The concept is coherent and the side-effect profile looks mild, but with no human trial evidence this remains an unproven, experimental compound rather than a validated heart treatment.